A Clinical Study to Investigate the Effects of Dapagliflozin on Heart Work, Heart Nutrient Uptake, and Heart Muscle Efficiency in Type 2 Diabetes Patients

NCT ID: NCT03387683

Last Updated: 2020-04-27

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE4
• Total Enrollment: 53 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2018-02-28
• Study Completion Date: 2019-03-19

Brief Summary

This is a randomised, placebo-controlled, double-blind, parallel-group, international, multicentre, Phase IV study to investigate the effects of dapagliflozin on cardiac substrate uptake, myocardial efficiency and myocardial contractile work in T2D patients. Eligible subjects with T2D before randomisation and fulfilling all of the inclusion criteria and none of the exclusion criteria will be randomised in a 1:1 ratio to dapagliflozin 10 mg or placebo once daily and treated for six weeks. The study includes five visits.

Detailed Description

The following will be assessed at Baseline and at the end of the treatment period;

1. MRI scanning in order to assess cardiac function and morphology. The MRI scanning will be made after fasting for at least 6 hours in the same time of day at all visits. The cardiac MRI examination will be performed in accordance with a pre-defined MRI protocol, with the total scan time at each visit estimated to 45 minutes. Images from all sites will be analyzed centrally at the core-lab using a dedicated software package and certified analysts.

2. CT-PET scanning will be made to assess myocardial function and metabolism, as well as fatty acid metabolism in brain, liver and kidney cortex. The CT-PET scanning will be made after a fast as well as abstinence from nicotine, alcohol and caffeine for at least 6 hours at the same time of day at all visits.

• A cardiac 11C-Acetate PET/CT examination is performed (IV 400 MBq 11C-Acetate).
• A cardiac 18F-FTHA PET/CT examination is performed (IV 150 MBq 18F-FTHA). The subject is further examined by PET/CT over the liver, kidney cortex and brain (in this order) for uptake of 18F-FTHA. Arterialized venous samples are acquired throughout to assess P-NEFA and 18F-FTHA metabolism by metabolite analysis

Conditions

Diabetes Mellitus Type 2

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: TRIPLE

Study Groups

placebo

placebo tablets once daily

Group Type: PLACEBO_COMPARATOR

placebo

Intervention Type: DRUG

placebo to match dapagliflozin

dapagliflozin 10mg

dapagliflozin 10mg tablets once daily

Group Type: EXPERIMENTAL

dapagliflozin

Intervention Type: DRUG

dapagliflozin 10mg

Interventions

dapagliflozin

dapagliflozin 10mg

Intervention Type: DRUG

placebo

placebo to match dapagliflozin

Intervention Type: DRUG

Other Intervention Names

Forxiga 10mg

Eligibility Criteria

Inclusion Criteria

• Capable of giving signed informed consent which includes compliance with the requirements and restrictions listed in the informed consent form (ICF) and in this protocol.
• Provision of signed and dated, written informed consent form prior to any mandatory study specific procedures, sampling, and analyses.
• Females or males ≥40 years up to 75 years of age.
• Individuals with type 2 diabetes diagnosed for at least 6 months based on the American Diabetes Association standards (ADA, 2017) and on stable dose of metformin for at least 6 weeks prior to screening and HbA1c at screening visit of ≥42 mmol/mol (6.0%) and ≤75 mmol/mol (9.0%) measured at local hospital laboratory.
• No significant signs or symptoms of coronary artery disease or, if known coronary artery disease, currently free of symptoms and a) all major epicardial vessels with <50% stenosis within 12 months prior to screening, or b) if revascularized with all major epicardial vessels with <50% remaining stenosis after stenting or bypass surgery procedure determined between 3 and 12 months prior to screening.
• Normal left ventricular ejection fraction (≥50%) assessed within 1 year prior to informed consent, and if applicable, after most recent acute episode of coronary artery syndrome, or at screening visit.
• Body mass index (BMI) ≥ 25 kg/m2.

Exclusion Criteria

• Blood pressure at screening that would require a change in blood pressure treatment over the study period or any of the following: systolic blood pressure >160 mmHg or diastolic blood pressure >100 mmHg.
• History of stroke or other clinically significant cerebrovascular disease.
• Any of the following cardiovascular diseases known within 3 months prior to signing the consent at enrolment:

1. Atrial fibrillation, or other unstable or severe arrhythmia affecting heart function

2. Unstable heart failure or any heart failure with NYHA class III and IV

3. Significant valvular disease

4. Significant peripheral artery disease

• Planned cardiac surgery or angioplasty within 3 months from enrolment.
• Clinical diagnosis of type 1 diabetes, maturity onset diabetes of the young (MODY), secondary diabetes or diabetes insipidus.
• Verified body weight variability of >3 kg during the 3 proceeding months before screening.
• Active malignancy requiring treatment at the time of visit 1 (with the exception of successfully treated basal cell or treated squamous cell carcinoma).
• Patients with severe hepatic impairment (Child-Pugh class C).
• Unstable or rapidly progressing renal disease.
• Clinically significant disease or disorder which, in the opinion of the investigator, may either put the subject at risk because of participation in the study, or influence the results or the subject's ability to participate in the study.
• Ongoing treatment with other antidiabetic drugs than metformin.
• Ongoing treatment with loop diuretics.
• Ongoing weight-loss diet (hypocaloric diet) or use of weight loss agents.
• Contraindications to dapagliflozin therapy.
• Ongoing treatment with systemic steroids at time of informed consent or change in dosage of thyroid hormones within 6 weeks prior to informed consent or any other uncontrolled endocrine disorder except for T2D.
• Previous enrolment in the present study or participation in another clinical study with an investigational product during the last 1 month prior to screening.
• Estimated Glomerular Filtration Rate (eGFR) <45 mL/min/1.73 m2.
• Alcohol or drug abuse within the 3 months prior to informed consent that would interfere with trial participation or any ongoing condition leading to a decreased compliance to study procedures or study treatment intake.
• Any condition when MRI and CT-PET is contraindicated such as, but not limited to, having a metallic implant (such as pacemaker or cochlear implant), permanent make up, claustrophobia or BMI ≥40 kg/m2).
• Involvement in the planning and/or conduct of the study.
• Plasma donation within one month of screening or any blood donation/blood loss >450 mL during the 3 months prior to screening.
• Women who has a positive pregnancy test at enrolment or randomization, or are breastfeeding.

• Minimum Eligible Age: 40 Years
• Maximum Eligible Age: 75 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

AstraZeneca

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Jonas Oldgren, MD, PhD

Role: PRINCIPAL_INVESTIGATOR

Uppsala Clinical Research Center, Upppsala Sweden

Pirjo Nuutila, MD, PhD

Role: PRINCIPAL_INVESTIGATOR

University of Turku, Turku, Finland

Locations

Research Site

Turku, , Finland

Research Site

Uppsala, , Sweden

Countries

Finland; Sweden

Provided Documents

Document Type: Statistical Analysis Plan

View Document

Document Type: Study Protocol

View Document

Related Links

https://filehosting-v2.pharmacm.com/api/Attachment/Download?tenantId=80217111&parentIdentifier=D1690C00063&attachmentIdentifier=fab41a7e-3728-4449-af49-b295cc99007e&fileName=D1690c00063-redacted_SAP_-Final_from_PRS.pdf&versionIdentifier=

redacted SAP

https://filehosting-v2.pharmacm.com/api/Attachment/Download?tenantId=80217111&parentIdentifier=D1690C00063&attachmentIdentifier=bb010979-d9fe-4e2f-bf31-506b76fa8ffa&fileName=D1690C00063-redacted_CSP_from_PRS.pdf&versionIdentifier=

redacted CSP

Other Identifiers

2017-003820-58

Identifier Type: EUDRACT_NUMBER

Identifier Source: secondary_id

D1690C00063

Identifier Type: -

Identifier Source: org_study_id